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Long-term changes in the immune system of successfully treated people living with HIV
(PLHIV) remain incompletely understood. In this study, we assessed 108 white blood cell
(WBC) populations in a cohort of 211 PLHIV on stable antiretroviral therapy and in 56 HIV-
uninfected controls using flow cytometry. We show that marked differences exist in T cell
maturation and differentiation between PLHIV and HIV-uninfected controls: PLHIV had
reduced percentages of CD4+ T cells and naïve T cells and increased percentages of
CD8+ T cells, effector T cells, and T helper 17 (Th17) cells, together with increased Th17/
regulatory T cell (Treg) ratios. PLHIV also exhibited altered B cell maturation with reduced
percentages of memory B cells and increased numbers of plasmablasts. Determinants of
the T and B cell composition in PLHIV included host factors (age, sex, and smoking),
markers of the HIV reservoir, and CMV serostatus. Moreover, higher circulating Th17
percentages were associated with higher plasma concentrations of interleukin (IL) 6,
soluble CD14, the gut homing chemokine CCL20, and intestinal fatty acid binding protein
(IFABP). The changes in circulating lymphocytes translated into functional changes withorg April 2021 | Volume 12 | Article 6619901
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Frontiers in Immunology | www.frontiersin.reduced interferon (IFN)- g responses of peripheral blood mononuclear cells to stimulation
with Candida albicans and Mycobacterium tuberculosis. In conclusion, this
comprehensive analysis confirms the importance of persistent abnormalities in the
number and function of circulating immune cells in PLHIV on stable treatment.Keywords: HIV, Th17 & Tregs cells, CD4+/CD8+ lymphocytes, B cell, HIV reservoir, CMV, Interferon gama (IFN-g),
Natural killer cell (NK cells)INTRODUCTION
Combination antiretroviral therapy (cART) has drastically
curtailed morbidity and mortality in people living with HIV
(PLHIV) (1). Still, PLHIV remain at an increased risk for
pneumococcal infections, Mycobacterium tuberculosis (M.
tuberculosis) reactivation and impaired vaccine responses (2–
6). Moreover, HIV infection predisposes to non-infectious
comorbidities, such as cardiovascular disease and non-AIDS-
related cancer, which share an underlying pathophysiological
pathway characterized by a persisting and inappropriate
activation of innate and adaptive immune cells (7, 8).
Together, these observations point towards a disbalance in the
homeostasis of the immune system, characterized by
immunodeficiency on the one hand, and chronic inflammation
on the other hand.
HIV-1 preferentially infects and kills activated CD4+ T cells,
leading to rapid and severe CD4+ T cell depletion in the gut and
increased microbial translocation (9–12). A small proportion of
these cells remains latently infected with replication competent
virus and defective proviruses, called the HIV-1 reservoir (13).
The HIV-1 reservoir and increased microbial translocation,
together with lifestyle factors and co-infections such as
cytomegalovirus (CMV) may all contribute to the disrupted
immune function in PLHIV (10, 13–17). However, published
data have shown inconsistent or even contradictory findings.
Heterogeneity in study populations, limited sample sizes of study
populations and differences in lifestyle factors, including use of
tobacco and recreational drugs, may underlie these
inconsistencies and emphasize the need for an integrative
approach in evaluating the immune system in PLHIV on
stable cART.
The Human Functional Genomics Project (HFGP) aims to
disentangle variation in the immune system in different cohorts
of healthy individuals and individuals with underlying
conditions. It combines multiple levels of analyses and data
integration, including demographic and lifestyle data, data
from ‘omics technologies’, and functional immune data (18).
As part of this project, we previously identified relevant
environmental and host factors for circulating white blood cell
(WBC) populations in healthy individuals (19). Embedded
within the HFGP, we established a cohort of 211 virally
suppressed PLHIV (200HIV) and showed that these
individuals exhibited a sustained pro-inflammatory immune
phenotype with priming of the interleukin (IL)-1b pathway
(20). In the present study, we used the same cohort to
comprehensively assess the peripheral WBC compositionorg 2during treated HIV infection with a special focus on the
adaptive immune system. We compared their WBC
populations with those of healthy individuals and assessed
associations with demographic and lifestyle factors, different
HIV-specific factors, and ex vivo cytokine responses of
peripheral blood mononuclear cells (PBMCs) to stimulation
with different bacterial, fungal and viral antigens.METHODS
Study Population
This study is part of the HFGP (www.humanfunctionalgenomics.
org) (18). Between 14 December 2015 and 6 February 2017,
individuals living with HIV were recruited from the HIV clinic of
Radboud university medical center. Inclusion criteria were
Caucasian ethnicity, age ≥ 18 years, receiving cART > 6 months,
and latest HIV-RNA levels ≤200 copies/ml. Exclusion criteria were:
signs of acute or opportunistic infections, antibiotic use <1 month
prior to study visit, and active hepatitis B/C. The control population
consisted of 56 healthy adult individuals (56P cohort), who did not
suffer from any acute or chronic conditions and who were
longitudinally sampled four times in three-month intervals.
Inclusion, sampling and sample processing of both cohorts were
conducted simultaneously and by the same personnel. The 56P
participants were selected as a subset of a larger cohort of 534
healthy individuals (500FG) which was phenotypically assessed two
years earlier according to the same methods (19, 21). Differences in
cell-cell associations were compared between 200 HIV and 500FG
cohort. The reason is that the larger sample size of this control
cohort (n=534 vs n=56) improved statistical power, whilst batch
effects between PLHIV and 500FG were deemed of less significance
when comparing within-group correlations between cohorts.
General information from all participants was recorded in the
Castor Electronic Data Capture program (Castor EDC, CIWIT
B.V., Amsterdam, The Netherlands), using questionnaires on socio-
demographic information, lifestyle and life-events. Clinical data
were extracted from medical files and the ‘Stichting HIV
Monitoring’ registry (Amsterdam, The Netherlands).
Ethics
The study protocols were approved by the Medical Ethical
Rev iew Committee reg ion Arnhem-Ni jmegen (ref .
42561.091.122) and conducted in accordance with the
principles of the Declaration of Helsinki. All study participants
provided written informed consent.April 2021 | Volume 12 | Article 661990
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Venous blood was collected in sterile 10 ml EDTA BD
Vacutainer® tubes between 8 and 11 am and processed within
1-4 hours. Cell counts were determined using a Sysmex XN-450
automated hematology analyzer (Sysmex Corporation, Kobe,
Japan). Erythrocyte-lysed whole blood samples were obtained
after 10 minutes incubation of 1.5 ml EDTA-anticoagulated
blood with lysis buffer containing 3.0 M NH4Cl, 0.2 M KHCO3
and 2 mM Na4EDTA. The remaining WBC were washed twice,
by adding 25 ml phosphate-buffered saline 1x (PBS, Braun,
Melsungen, Germany) and centrifuging at 452 x g for 5 min at
room temperature. Before staining, cells were resuspended in 300
ml of PBS enriched with 0.2% bovine serum albumin (BSA,
Sigma-Aldrich, Zwijndrecht, Netherlands). Isolation of PBMCs
was performed by density centrifugation of EDTA-
anticoagulated blood diluted 1:1 in pyrogen-free PBS over
Ficoll-Paque (VWR, Amsterdam, The Netherlands) as
described previously (22). Cells were adjusted to 5.0 x 106
cells/ml.
Flow Cytometry
Supplementary Table 1 summarizes the antibody clones and the
fluorochrome conjugates used for the different panel fluorescent
staining mixes. Staining was performed on 100 ml/well
erythrocyte-lysed blood (panel 1-3,5) or 0.5 x 106 cells/well
freshly isolated PBMCs (panel 4). Cells were stained according
to previously described procedures (see also Supplementary
Methods) (19).
Samples were measured on a 10-color Navios flow cytometer
(Beckman Coulter, Fullerton, CA, USA), equipped with three
solid-state lasers (488 nm, 638 nm, and 405 nm) (19). Gating was
conducted manually and verified by two independent specialists
to prevent gating errors. Samples were analyzed within 4-5 hr
after blood collection, using five distinct and complementary 10-
color antibody panels: 1. general; 2. T cell; 3. B cell; 4.
intracellular T cell/Treg; 5. chemokine receptors (CCR).
Staining and gating strategies can be found in Supplementary
Figure 1. Flow cytometry data were analyzed using Kaluza
software version 1.3. In our analyses, we focused on a set of
108 manually annotated WBC subsets based on the original
500FG study (panel 1-4) (19), with the addition of a fifth panel in
which we classified monocytes, CD4+ memory and regulatory T
cells, and CD8+ cells according to their expression of the
CXCR3, CCR4, and CCR6 (panel 5).
PBMC Stimulation Experiments
Freshly isolated PBMCs were incubated with different stimuli
(Supplementary Table 2) including bacterial (Staphylococcus
aureus , M. tuberculosis, Streptococcus pneumoniae [S.
pneumoniae]), fungal (Cryptococcus gattii, Candida albicans [C.
albicans] hyphae and yeast) and other relevant antigens
(Imiquimod, TLR7 ligand), in round-bottom 96-well plates
(Greiner Bio-One, Frickenhausen, Germany) with 0.5 x 106
cells/well at 37°C and 5% CO2 in the presence of 10% human
pooled serum for seven days. Supernatants were stored at -20°C.
Levels of the lymphocyte-derived cytokines IL-17, IL-22, andFrontiers in Immunology | www.frontiersin.org 3interferon (IFN)-g were measured in the supernatants (PeliKine
Compact or Duoset ELISA, R&D Systems).
Plasma Markers
Serum levels of immunoglobulin (Ig)M and IgG were measured
by immunonephelometry using a Beckman Coulter Imager and
Beckman Coulter reagents. Measurements were standardized
using certified European reference material 470 (ERM®-
DA470). CMV IgG antibodies were measured in serum using
ELISA (Genway Biotech Inc., San Diego, CA, USA) according to
the manufacturer’s instructions. Markers of systemic
inflammation, high-sensitive C-reactive protein (hsCRP) and
soluble CD14 (sCD14), and microbial translocation, intestinal
fatty acid binding protein (IFABP), were measured by ELISA
(Quantikine, R&D Systems) according to the manufacturer’s
instructions. IL-6 was measured using a SimplePlex Cartridge
(Protein Simple, San Jose, CA, USA). Circulating plasma CCL20,
IL-17A, and IFN-g were measured using the commercially
available Olink Proteomics AB Inflammation Panel as
described previously (23, 24).
Cell-Associated HIV-1 DNA and Cell-
Associated HIV-1 RNA Quantification in
CD4+ T Cells
The HIV reservoir was assessed by analyzing CD4+ cell-
associated HIV-1 DNA (CA-DNA) and CA-RNA. In virally
suppressed patients, the CA-DNA roughly equals the
integrated HIV-1 DNA, being replication competent or not
(25), while CA-RNA is associated with recent HIV-1
transcriptional activity and serves as a proxy for the active
proviral reservoir (26). CA-DNA and CA-RNA were measured
in triplicate by droplet digital PCR (ddPCR – Bio-Rad) in CD4+
T cells isolated using EasySep Human CD4+ T Cell Isolation Kit
(Stemcell technologies, Vancouver, Canada) as described
previously (27). CA-DNA was extracted by the DNeasy Blood
& Tissue kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol with the addition of 75µl elution
buffer on the column heated at 56°C for 10 minutes. CA-RNA
was extracted using the Innuprep RNA kit (Westburg, Leusden,
The Netherlands) with 30µl elution buffer. Total RNA was
reversely transcribed to cDNA by qScript cDNA SuperMix
according to manufacturer’s protocol (Quantabio, Beverly, MA,
USA). CA-DNA was normalized by measuring the reference
gene RPP30 (Supplementary Table 3 and Supplementary
Methods) in duplicate by ddPCR and expressed per million
CD4+ T cells. CA-RNA was normalized using three reference
genes per patient, (B2M, ACTB and GADPH), which were
measured with LightCycler 480 SYBR Green I Master mix.
HIV-1 RNA copies were divided by the geometric mean of the
reference genes and expressed per million PBMCs. ddPCR data
analysis was performed using the ddpcRquant tool with standard
settings for thresholding and absolute quantification (28).
Statistical Analyses
A detailed description of the statistical methods can be found in
the Supplementary Methods. Given the impact of cohortApril 2021 | Volume 12 | Article 661990
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CD4+) on the numbers of their subsets (e.g. CD4+ regulatory T
cells [Tregs]), results were primarily reported as WBC
percentages, unless stated otherwise. WBC percentages were
calculated by dividing the cell count of each subpopulation by
its respective parent (one level up) or, where relevant,
grandparent (two levels up; Supplementary Table 4). Data
curation of cytokine, soluble marker, and immunoglobulin data
was done according to previous methods (21). For comparisons
between cohorts, we used all four longitudinally collected data
points from the 56P cohort as independent measurements.
Because of the known seasonality effects on WBC, this
approach was considered preferable over selecting one of the
data collection points or summarizing the data points. Data were
normalized using an inverse rank transformation algorithm.
Comparisons in baseline characteristics between groups were
made using Student’s t-test (or Mann-Whitney U test) for
continuous variables, and Pearson’s Chi-square test (or Fisher’s
exact) for categorical variables. Linear regression was used to
compare WBC between cohorts, and to calculate associations
between WBC and clinical and virological factors. All analyses
were corrected for age, sex, time since January 2015 and seasonal
effects. Cytokine analyses between cohorts were also corrected
for CD4+ and CD8+ T cell percentages. Spearman correlationsFrontiers in Immunology | www.frontiersin.org 4were used as the distance metric for unsupervised hierarchical
WBC count clustering. Two-sided FDR-corrected p-values <
0.05 were considered statistically significant (29). Effect sizes
are reported as Spearman’s Rho or standardized beta coefficients
(b). Data were analyzed using the statistical programming
language R (version 3.4.3, R Core Team, 2012).RESULTS
General and HIV-Specific Characteristics
Data from 211 PLHIV and 56 controls were analyzed in this
study (Table 1). PLHIV were older (median [IQR] 52.5 [46.2 –
59.4] vs 30.0 [25.1 – 52.2] years, p<0.0001) and more often male
(193/211 [91.5%] vs 34/56 [60.7%], p<0.0001) than controls.
PLHIV had received cART for a median of 6.6 (4.2–11.9) years
and 205/210 (98%) had plasma HIV-1 RNA <50 copies/mL at
time of study visit. Analyzing the HIV reservoir, we found
detectable levels of total CA-DNA in 207/208 (99.5%) and
CA-RNA in 210/210 (100%); CA-DNA and CA-RNA levels
were highly correlated (Supplementary Figure 2A; R=0.68,
p<2.2·10-16). In general, PLHIV with higher CA-DNA and
CA-RNA levels were older, had been living with and treatedTABLE 1 | General characteristics.
Characteristic PLHIV (n = 211) HC (n = 56) P-value
Age, years 52.5 (46.2 – 59.4) 30.0 (25.1 – 52.2) <0.0001
Sex, female, n/N (%) 19/211 (9.0) 22/56 (39.3) <0.0001
BMI, kg/m2 24.2 (22.1 – 26.1) 23.6 (21.6 – 25.2) 0.41
Time since HIV diagnosis, years 8.5 (9.5) – –
Way of transmission, n/N (%) – –
MSM 159/211 (75.4) – –
Heterosexual contact 9 (4.3) – –
IDU 3 (1.4) – –
Other or unknown 40 (19.0)
Nadir CD4+ cell count, cells/ml 250 (130 - 360) – –
CD4+ count, cells/ml 660 (480 - 810) – –
Zenith HIV-RNA, copies/mL 100 000 (50 000 - 391182) – –
HIV-RNA >50 copies/mL ≤1 yr. prior to inclusion, n/N (%) 23/210 (11.0) – –
CA-DNA (copies per million CD4+ cells) 1547 (584 - 2802)
CA-RNA (copies per million CD4+ cells) 157 (74 - 299)
cART-naive, n/N (%) 30/211 (14.2) – –
Time on cART, years 6.6 (4.2 – 11.9) – –
ARV classes, n/N (%)
NNRTI 63/211 (29.9) – –
PI 32/211 (15.2) – –
INSTI 141/211 (66.8) – –
Co-medication, n/N (%)
Cholesterol lowering drugs 58/211 (27.5) – –
Antihypertensive drugs 50/211 (23.7) – –
Metformin 9/211 (4.3) – –
Active smoking, n/N (%) 63/211 (29.9) 2/56 (3.6) <0.0001
Heavy drinking, n/N (%)* 28/211 (13.3) 11/56 (19.6) 0.29
Regular substance use, n/N (%)† 61/211 (28.9) 3/56 (5.4) <0.0001April 2021 | Volume 12 | ArticleData depicted as median (IQR) unless stated otherwise. Data analyzed using Mann-Whitney U or c2 (or Fisher’s exact) where applicable.
*Classified according to the CDC definition: for men, ≥15 drinks per week and for women, ≥8 drinks/week.
†Defined as use of any psychoactive substance (with the exception of alcohol and tobacco) during periods ≥ 1 time per week including ≥ 1 time during the 30 days prior to the study visit.
ARV, antiretroviral drug; BMI, body mass index; CA-DNA, CD4-cell-associated HIV-1 DNA; CA-RNA, CD4-cell-associated HIV-1 RNA; HC, healthy control; cART, combination
antiretroviral therapy; INSTI, integrase inhibitor; IDU, intravenous drug use; MSM, men who have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; PLHIV, people living
with HIV; PI, protease inhibitor.661990
Van de Wijer et al. Generalized Immune Dysregulation in HIVfor HIV for a longer period, and had lower nadir CD4+ T cell
counts (Supplementary Figure 2A). We observed no significant
differences in CA-RNA and CA-DNA between PLHIV with
plasma HIV-1 RNA <50 copies/mL (205/210 [98%]) and those
with plasma HIV-1 RNA 50-200 copies/mL (5/210 [2%];
Supplementary Figure 2B). PLHIV with at least once a viral
load of >50 copies/mL during year prior to study visit (23/210
[11.0%]) had higher levels of CA-RNA (p=0.0077), but no
differences in CA-DNA (p=0.076; Supplementary Figure 2B).
Alterations in WBC Composition and Cell-
Cell Associations in Chronic HIV
We analyzed 108 WBC populations, including 93/107 (87%) B
and T cell subsets and 14/107 (13%) innate cell subsets
(neutrophils, monocytes, natural killer [NK] and natural killer
T cells [NKT]). Figure 1 and Supplementary Figure 3 show the
differences in WBC composition between PLHIV and controls.
An overview of median (IQR) WBC percentages and numbers in
PLHIV and controls can be found in Supplementary Table 5.
Principal component analysis (PCA) of all WBC populations
only explained a limited amount of the total variance. Still, the
PCA plot showed clear differences in clustering between PLHIV
and controls (Figure 1A). As expected, PLHIV exhibited an
expansion of CD8+ and a reduction of CD4+ T cell numbers and
percentages (Figure 1B and Supplementary Table 5).
Functionally, CD4+ T cells comprise a diverse population of
cells. CD4+ T helper (Th) cells fulfill essential roles for viral (Th1,
CCR6-CXCR3+CCR4-), parasitic (Th2, CCR6-CXCR3-CCR4+),
and mucosal (Th17, CCR6+CXCR3-CCR4+) immunity (30). In
addition, CD4+ Tregs are essential for controlling inflammation
(31). Despite reduced CD4+ T cell counts, numbers of all Th cell
subsets (CD4+ CD45RA- CD25-) were markedly increased in
PLHIV compared to controls (Figure 1B and Supplementary
Table 5). Within the Th pool, Th2 percentages were reduced in
PLHIV compared to controls, whereas Th1 percentages did not
differ. Remarkably, Th17 percentages and numbers were
increased in PLHIV (Figures 1B, C and Supplementary
Table 5). While Treg percentages (of CD4+ cells), including
highly suppressive Tregs co-expressing the transcription factors
FoxP3 and Helios, were also increased in PLHIV, absolute Treg
numbers were reduced (Figures 1B, C and Supplementary
Table 5). This relative increase of Tregs may result from a loss
of other CD4+ subsets (32). Among Tregs, we found no
differences in the percentage of activated (HLA-DR+) and
effector Tregs (CD45RA-). The relationship between pro-
inflammatory Th17 cells and Treg must remain balanced to
preserve functional immunity. Altered ratios have been described
in untreated HIV (lower Th17/Treg), autoimmune disease and
cancer (higher Th17/Treg) (9, 33, 34). Here, we found increased
Th17/Treg ratios among virally suppressed PLHIV, irrespective
of the Treg identification marker used (Figure 1C and
Supplementary Figure 4). Furthermore, out of the Treg
population, the percentage of Th17-like CCR6+ Tregs was
increased in PLHIV, further contributing to a pro-
inflammatory state. Developmentally, T cells evolve from naive
T cells to antigen experienced central memory (CM), effector
memory (EM), and effector cells (35, 36). HIV not onlyFrontiers in Immunology | www.frontiersin.org 5differentially affects functional subpopulations, but also
disrupts these developmental stages. While naïve CD4+ and
CD8+ T cells were reduced, memory and effector cells were
expanded in PLHIV (Figure 1B and Supplementary Table 5).
Likewise, we found higher percentages of proliferating (Ki67+)
CD4+ and CD8+ T cells in PLHIV, indicating increased cell
turnover. These results suggest a shift from naive cells towards
terminally differentiated cells in HIV, even if viral replication is
under control (37), which cannot be explained by age, sex, or
season as we corrected our models for these factors.
Changes in the B cell compartment have also been described in
PLHIV, including loss of CD27+ memory B cells (38, 39).
Furthermore, viremia and low CD4+ T cell counts have been
associated with the expansion of terminally differentiated B cells
and immature B cells respectively (38, 39). In our study, we
observed clear differences in B cell development in PLHIV
illustrated by increased percentages of naïve B cells (IgD+IgM+
CD27-) and reduced percentages of memory B cells (IgD+IgM+
CD27+), transitional B cells (CD24++CD38++) and natural
effector B cells (CD24+CD38+IgD+IgM+). In addition, the
number of plasmablasts (IgD- IgM- CD38++) was increased in
PLHIV, (Figures 1B, C and Supplementary Table 5). Adequate B
cell maturation further requires optimal communication between
B and T cells. We therefore sought to identify differences in WBC
co-regulation between PLHIV and HIV-uninfected individuals by
comparing cell-cell associations between PLHIV and participants
from the 500FG cohort. Details of this 500FG cohort have been
reported previously (500FG, n=534) (19). Using the same
immunophenotyping techniques, we observed weaker
correlations between naïve, CM and EM CD4+ T cells and
several B cell subpopulations (including class-switch memory B
cells) within PLHIV than in participants of the 500FG cohort,
suggesting altered B/T cell interactions (Figure 2). These
differences were not attributable to the influence of age, sex, or
season as these factors were regressed out of the analysis.
Apart from changes in the adaptive cell compartment, we
observed clear changes in the innate WBC compartment in
PLHIV. Monocyte and NKT cell numbers and percentages were
increased, whereas NK cell numbers and percentages were
reduced, specifically the cytokine-producing NK bright cells
(Figure 1B and Supplementary Table 5) Together, these data
show a widespread functional and developmental dysregulation of
the immune system in virally suppressed PLHIV. This
dysregulation encompasses both the innate and the adaptive
compartment and results in a pro-inflammatory immune
environment with an expansion of monocytes, pro-inflammatory
Th and effector T cells, and dysregulated B cell memory responses.
Lifestyle, Demographic, and Clinical
Factors Influence the WBC Composition
During Chronic HIV Infection
Apart from the effects of HIV, demographic and lifestyle-related
factors may influence the composition of the circulating WBC
populations. Indeed, we found that older age was associated with
an increase of innate immune cells and differential effects on B
and T cell populations, for example with lower percentages of
naïve T cells (CD4+ T cells b=-0.29, p=0.00020; CD8+ T cellsApril 2021 | Volume 12 | Article 661990
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FIGURE 1 | Differences in WBC percentages between PLHIV and healthy individuals (A) Principal component biplot showing standardized variance for the two
principal component of all WBC subsets. The ovals represent the different cohorts. (B) Differences in WBC percentages (n=108 WBC subsets) between PLHIV
(n=211) and healthy controls (n=56) (C) Boxplots showing examples of cohort differences in cell percentages and Th17/Treg ratios (Treg identification marker
CD25++). Inverse-rank transformed data were analyzed using multiple linear regression and adjusted for age, sex, sampling time, and season. For color coding of
the FDR-adjusted p-values see legend.Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 6619906
Van de Wijer et al. Generalized Immune Dysregulation in HIVb=-0.29, p=0.00020) and B memory cells (b=-0.39, p=1.5·10-7)
and higher percentages of memory T cells (e.g. CD8+ CM
b=0.22, p=0.00064) and mature naïve B cells in PLHIV
(b=0.25, p=0.00087, Figure 3 and Supplementary Table 6).
Sex-dependent influences of the WBC composition, reflected
by more effector and EM cells and fewer naïve (B and T) cells in
males in HIV infection, resembled those observed previously
observed in healthy individuals (21, 40).
Lifestyle risk behaviors such as smoking [63/211 (29.9%)],
heavy drinking [28/211 (13.3%)], and regular drug use [61/211
(28.9%)] were highly prevalent in PLHIV (Table 1). We found
that packyears (reflecting total tobacco exposure) were associated
with higher frequencies of neutrophils (b=0.22, p=0.033), Treg
(b=0.22, p=0.033), CD8+ subsets (e.g. CCR6-CXCR3-CCR4+
b=0.24, p=0.025), and class switched memory B cells (b=0.20,
p=0.042, Supplementary Table 6). Active smoking correlated
with higher percentages of Th17 (b=0.21, p=0.031) and CCR6+
Tregs (b=0.26, p=0.0028, Figure 3 and Supplementary Table 6).
Neither heavy drinking, nor regular drug use affected the
WBC composition.Frontiers in Immunology | www.frontiersin.org 7We further assessed the effects of relevant clinical factors on
the WBC composition in PLHIV, by exploring associations with
the history of immune suppression and treatment-related
factors. We found that nadir CD4+ cell counts were closely
associated with both B and T cell percentages in PLHIV
(Figure 3 and Supplementary Table 6). For example, higher
counts were associated with higher percentages of naïve CD4+ T
cells (b=0.45, p=1.2·10-9) and memory B cells (b=0.18, p=0.034).
In contrast, we observed no effects of the duration of HIV
infection or cART (regimen) on the WBC composition
(Supplementary Tables 6).
HIV-1 Reservoir and CMV Affect the WBC
Composition in Chronic HIV Infection
First, we explored the relationship with markers of the HIV
reservoir. CA-DNA was negatively associated with CD4+ T cell
percentages (b=-0.33, p=9.8·10-5) and positively with CD8+ T
cell percentages (b=0.34, p=7.0·10-5). Within the CD4+ T cell
pool, CA-DNA correlated with higher percentages of CM and
Th17 cells (b=0.21, p=0.026 and b=0.24, p=0.0081 respectively;FIGURE 2 | Differences in cell-cell associations between PLHIV and healthy individuals. Exploratory analysis depicting cell-cell associations between a total of 77
available WBC subsets that were significantly stronger (red) or weaker (blue) in PLHIV compared to healthy controls (n=534). FDR-adjusted p-values are obtained
after 10 000 permutations and adjusted for age, sex, sampling time and season. HC, healthy control; PLHIV, people living with HIV; WBC, white blood cells.April 2021 | Volume 12 | Article 661990
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associated with more CD4+ T cell proliferation (Ki67+, b=0.35,
p=3.3·10-5) and Treg activation (HLA-DR+, b=0.23, p=0.0081).
We found similar associations between T cells and CA-RNA,
whereas we found no relation between T cells and the
relative HIV transcription level (CA-RNA/CA-DNA ratios;
Supplementary Table 7). Lastly, we observed several
associations between CA-DNA and B cells: higher CA-DNA
levels correlated with reduced percentages of IgD+ only memory
B cells (b=-0.27, p=0.00068) and, albeit non-significantly, with
reduced percentages of natural effector B cells (CD24+CD38+Frontiers in Immunology | www.frontiersin.org 8IgD+IgM+, b=-0.18, p=0.056), and class unswitched memory B
cells (IgD+IgM+CD27+, b=-0.18, p=0.053). Exclusion of PLHIV
with HIV-RNA 50-200 copies/mL at time of study visit (5/210
[2%]) did not change the main conclusions of our paper
(Supplementary Tables 8, 9).
Second, CMV co-infection may contribute to immune
dysregulation in both treated and untreated PLHIV. As CMV
is known to affect WBC populations in healthy controls (41), we
explored the association of CMV serostatus with WBC
composition. 198 of the PLHIV (93.8%) were seropositive for
CMV. In line with findings in healthy individuals (41), CMVA
B
FIGURE 3 | Clinical determinants of WBC percentages in PLHIV (A) Heatmap of WBC percentages (n=108 WBC subsets) that were significantly associated with
any of the clinical determinants tested in 211 PLHIV; WBC subsets that showed no significant correlations with any of the parameters (n=37) have been removed
from the figure. (B) Examples of WBC subsets that were significantly associated with age, sex, smoking, or CD4 nadir. Inverse-rank transformed data were analyzed
using linear regression and adjusted for age, sex, sampling time, and season. For color coding of the FDR-adjusted p-values see legend. PLHIV, people living with
HIV; WBC, white blood cells.April 2021 | Volume 12 | Article 661990
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T cells (e.g. with CD8+ effector cells b=0.43, p=1.7·10-9 and
CD4+ EM cells b=0.30, p=0.00011; Figure 4 and Supplementary
Table 7) and NKT cells (b=0.29, p=0.00029), yet with lower
percentages of Th17 cells (b=-0.26, p=0.00065). We observed no
associations between B cell subsets and CMV.
Microbial Translocation, Inflammation
and Th17 Differentiation in Chronic
HIV Infection
Our main findings include a loss of naïve T cells and an
expansion of Th17 in PLHIV compared to healthy controls,
which related with lower nadir CD4+ T cells counts and higher
levels of CA-DNA. To further assess the potential underlying
mechanisms, we explored the relationship between these WBC
subsets, markers of chronic inflammation, and markers of
microbial translocation. As discussed above, naïve T cells areFrontiers in Immunology | www.frontiersin.org 9able to differentiate into different Th subsets depending on the
cytokine environment (42). We previously showed that PLHIV
in our cohort exhibited a pro-inflammatory profile with
increased levels of hsCRP (p=0.00022) and sCD14 (a marker of
monocyte activation, p=0.0025; Figure 5A) as well as markedly
elevated monocyte-derived cytokine responses, particularly IL-
1b (20). Such a pro-inflammatory cytokine environment may
push the differentiation of naive CD4+ cells into Th17 cells (42).
Indeed, we observed positive associations between Th17
percentages and circulating IL-6 (b=0.21, p=0.014) and sCD14
(b =0.17, p=0.035; Figures 5B, C). Notably, Th17 cells fulfill an
essential role in mucosal defense and gut Th17 cells are known to
be severely depleted during acute HIV (9). To test whether gut
integrity might have been compromised in our cohort, we
measured levels of the microbial translocation marker IFABP
and found increased levels in PLHIV compared to healthy
controls (p=7.6·10-5; Figure 5D), suggesting ongoing microbialA B
FIGURE 4 | The HIV-1 reservoir, CMV serostatus and WBC percentages in PLHIV (A) Heatmap of significant associations between WBC percentages (total n=108),
CMV co-infection (serostatus and IgG titers in 198 seropositive PLHIV) and markers of the HIV-1 reservoir (CA -DNA and CA- RNA) in 211 PLHIV; WBC subsets that
showed no significant correlations with any of the parameters (n=41) have been removed from the figure. (B) Examples of WBC percentages that were significantly
associated with the viral reservoir or CMV IgG titers. Inverse-rank transformed data were analyzed using linear regression and adjusted for age, sex, sampling time,
and season. For color coding of the FDR-adjusted p-values see legend. CA-DNA, CD4-cell-associated HIV-1 DNA; CA-RNA, CD4-cell-associated HIV-1 RNA; CMV,
cytomegalovirus; PLHIV, people living with HIV; WBC, white blood cells.April 2021 | Volume 12 | Article 661990
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higher CA-RNA and CA-DNA (CA-RNA b =0.18, p=0.0091 and
CA-DNA b=0.21, p=0.0025, Figure 5E). Higher levels of IFABP
were associated with an expansion of peripheral blood Th17
(b=0.17, p0.043; Figure 5B). Homing of Th17 to the gut (and
other tissues, such as the skin) is directed by the chemokine
CCL20, which is produced by tissue and immune cells
(neutrophils and monocytes) and binds uniquely to the
CCR6+ receptor (43). Correspondingly, we found strong
associations between CCL20 and Th17 percentages (b=0.22,
p=0.0037), CCL20 and Th17/Treg (b=0.26, p=0.00081 for
Th17/FoxP3+ Treg, b=0.27, p=0.00081 for Th17/CD127lowFrontiers in Immunology | www.frontiersin.org 10Treg, and b=0.19, p=0.013 for Th17/CD25++ Treg), CCL20
and circulating IL-17A levels (b=0.47, p=1.2·10-11) and CCL20
and IFABP (b=0.24, p=0.0011; Figure 5F). Together, these
results suggest that the pro-inflammatory environment in
chronic HIV may promote the differentiation of circulating
naïve CD4+ T cells into Th17 cells and that these changes may
be associated with changes in gut permeability and gut homing.
Functional Consequences of Changes in
Adaptive Immune Cells in Chronic HIV
As our results indicated significant changes in circulating
immune cell populations in PLHIV, we next analyzed theA B
C D
E F
FIGURE 5 | Inflammation, microbial translocation, and Th17 cells in PLHIV (A) Boxplots showing differences in hsCRP and sCD14 between PLHIV (n=211) and
healthy controls (n=56). (B) Heatmap showing associations between Th17 percentages, Th17/Treg ratios and sCD14, hsCRP, IFABP, and CCL20. (C) Associations
between Th17 percentages and sCD14 and circulating IL-6 in PLHIV. (D) Levels of the microbial translocation marker IFABP in PLHIV and healthy controls.
(E) Associations between IFABP and CA-RNA and CA-DNA in PLHIV. (F) Associations between CCL20 and circulating IL-17A and IFABP. Inverse-rank transformed
data were analyzed using linear regression analyses and corrected for sampling time. CA-DNA, CD4-cell-associated HIV-1 DNA; CA-RNA, CD4-cell-associated
HIV-1 RNA; CCL20, Chemokine (C-C motif) ligand 20; HC, healthy control; hsCRP, high-sensitivity CRP; IFABP, intestinal fatty-acid binding protein; IL-6, interleukin
6; IL-17A, interleukin 17A; Mem Tc, CD4+ memory T cell; PLHIV, people living with HIV; sCD14, soluble CD14; Th17 percentages, T-helper 17 cell percentages
(Mem Tc CCR6+ CXCR3-CCR4+ as percentage of CD4+ Mem Tc); Treg, regulatory T cells; WBC, white blood cells.April 2021 | Volume 12 | Article 661990
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cytokine responses of PBMCs after stimulation with different
stimuli. We found strong correlations between NK and T-cell
percentages and ex vivo IFN-g, IL-17, and IL-22 responses
(Figure 6A and Supplementary Table 10): IFN-g responses
correlated with percentages of NK dim, CD4+ and CD8+ EM
cells, whereas IL-22 responses correlated with CCR6+ CM CD4+
cell percentages. As expected, Th17 percentages were associated
with increased circulating IL-17A (b=0.16, p=0.029) and ex vivo
IL-17 responses to C. albicans (b=0.19, p=0.047) and with
reduced IFN-g responses (Figures 6A, E and Supplementary
Table 10). Despite the expansion of Th17 cells among PLHIV
compared to controls, ex vivo responses of IL-17 or IL-22 did not
differ, suggesting that the functional capacity of these cells may
be compromised. In contrast, IFN-g production upon
stimulation with C. albicans hyphae (p=0.012) and M.
tuberculosis (p=0.0025) was reduced in PLHIV (Figure 6B).
Among PLHIV, lower ex vivo IFN-g production to stimulation
with Imiquimod (b =-0.21, p=0.0020) and S. pneumoniae (b=-
0.22, p=0.0011) and lower circulating IFN-g concentrations (b=-
0.18, p=0.014) were associated with higher CA-DNA levels
(Figures 6C, D). No associations were found between ex vivo
cytokine production and CMV seropositivity.
Second, we measured serum immunoglobulins and found
significant correlations between serum IgM and IgM+ B cell
populations (Figure 6F), but no cohort differences in IgM levels
[median (IQR) 0.76 (0.56 – 1.05) g/L in PLHIV versus 0.82
(0.65 – 1.21) g/L in controls, p= 0.22] or IgG levels [10.03 (8.34 -
11.59) g/L in PLHIV versus 9.10 (7.59 – 11.38) g/L in controls,
p= 0.12]. These results indicate that while some of the alterations
in adaptive immune function may be reversed by long-term
cART (44, 45), others, such as impaired IFN-g responses, remain.DISCUSSION
In this study we show that, despite suppressive cART, the
circulating innate and adaptive immune cell composition in
PLHIV differs from that of HIV-uninfected individuals. We
confirm that PLHIV exhibit a WBC profile characterized by
proliferating memory and effector CD4+ and CD8+ T cells.
While untreated HIV infection has been associated with a loss of
circulating Th17 cells (9), we observed an expansion of circulating
Th17 cells and increased Th17/Treg ratios during stable suppressive
treatment, which was associated with plasma concentrations of IL-
6, CCL20 and the microbial translocation marker IFABP.
Furthermore, PLHIV showed clear changes in B cell maturation
with reduced memory B cell percentages and increased plasmablast
numbers. In the innate compartment, we observed an expansion of
monocytes together with a loss of NK cells, specifically NK bright
cells. In addition to age, sex, smoking, and CMV, we found strong
associations between WBC populations and markers of the HIV-1
reservoir (CA-DNA and CA-RNA). Functionally, Th17 responses
seemed to be preserved, whereas IFN-g responses to C. albicans and
M. tuberculosis were compromised, especially in those with higher
CA-DNA. The compromised IFN-g responses may affect hostFrontiers in Immunology | www.frontiersin.org 11defense against some important bacterial pathogens (including
M. tuberculosis) and the HIV-1 reservoir.
Prior studies have shown that untreated HIV infection results in
a massive depletion of Th17 cells from the peripheral blood and the
mucosa (9), a process that may partially be reversed by cART (46–
48). We recently showed that PLHIV from the same cohort
exhibited a pro-inflammatory profile with increased monocyte-
derived cytokines, particularly IL-1b (20). IL-1b and IL-6 are
among the critical cytokines driving differentiation of Th17 (42),
and we postulate that these cytokines may have contributed to the
higher circulating Th17 numbers. Th17 cells in the peripheral blood
poorly reflect mucosal Th17 numbers (49) and it is possible that
mucosal Th17 depletion with increased microbial translocation and
altered Th17 recruitment occurs in the participants of our study.
The gut-inflammatory marker generating islet-derived protein 3a
(REG3a) would be of interest for future studies on the interplay
between Th17 and epithelial gut damage in PLHIV
(50).Concurrently to increased Th17 cells and pro-inflammatory
Th17-like (CCR6+) mTregs, PLHIV showed increased peripheral
blood Th17/Treg ratios. Increased Th17/Treg ratios have been
linked to cardiovascular disease and atherosclerosis (33), cancer
(34), and major depressive disorder (51), which are all highly
prevalent in long-term treated PLHIV. Th17-mediated auto-
immune diseases like psoriasis are also common among PLHIV,
although they mostly occur during periods of severe
immunosuppression and resolve upon cART initiation (52).
Despite these changes in Th17, IL-17 and IL-22 cytokine
responses did not differ between PLHIV and healthy controls. In
contrast, we observed reduced ex vivo IFN-g responses to C.
albicans and M. tuberculosis in PLHIV. IFN-g is predominantly
produced by NK(T) cells, Th1, and CD8+ cells (44). Given that
CD8+ cells were increased in PLHIV and Th1 cells did not differ
between PLHIV and controls, we postulate that the reduced IFN-g
responses may have resulted from the loss of NK cells, which has
been reported previously in both untreated and treated PLHIV (53,
54). In line with prior data, we observed an inverse relationship
between IFN-g responses and CA-DNA, suggesting that the failure
to restore the NK cell compartment after cART initiation may be
important for the containment of the HIV-1 reservoir
(55).Moreover, IFN-g is a key cytokine in the immune response
against M. tuberculosis which remains an important pathogen in
treated PLHIV (56). Improving IFN-g responses, may therefore be
relevant in the context of M. tuberculosis and HIV cure.
Different factors may contribute to the variation in T-cells
repertoire in PLHIV. First, the effects of demographic factors such
as age, sex, and smoking resembled those observed previously in
healthy individuals (19, 41). Second, PLHIV in our study were
almost universally coinfected with CMV and, in line with earlier
data in HIV-infected and uninfected individuals, CMV
seropositivity was associated with the expansion of effector and
EM CD4+ and CD8+ T cells (14, 41, 57, 58). Of note, high CMV
IgG levels may reflect frequent CMV reactivations or result from
a stronger immune response (including adequate B/T cell
interactions and B cell responses) and, consequently, fewer
activations (59). Importantly, higher CMV IgG titers have been
linked to microbial translocation and the development of non-
AIDS-defining events such as cardiovascular disease (14, 60).April 2021 | Volume 12 | Article 661990
Van de Wijer et al. Generalized Immune Dysregulation in HIVThird, we found substantial associations between WBC subsets
and CD4+ nadir and markers of the HIV-1 reservoir. Overall,
CA-DNA showed more and stronger correlations with WBC
subsets than did CA-RNA, which may be explained by the
fact that CA-RNA levels, reflecting transcriptional activity, are
low during viral suppression and subtle effects may be missed
(13, 61).Frontiers in Immunology | www.frontiersin.org 12Next to T cell dysfunction, HIV is characterized by aberrant
B cell responses and B cell dysfunction. Using a different set of
B cell markers than earlier studies in PLHIV (62, 63), we
confirm their observations that percentages of naïve B cells
are increased and memory B cells are reduced in PLHIV.
Moreover, adequate B cell maturation requires optimal




FIGURE 6 | Functional consequences of WBC alterations in PLHIV (A) Heatmap of NK(T) and T cell percentages (total n=71) that were significantly associated with
the ex vivo production of IFN-g, IL-17, and IL-22 upon seven days ex vivo stimulation of PBMCs with different stimuli (n=7) in 211 PLHIV; WBC subsets that showed
no significant correlations with any of the parameters (n=44) have been removed from the figure. (B) Boxplot showing differences in ex vivo IFN-g responses upon
stimulation with C. albicans and M. tuberculosis between PLHIV (n=211) and healthy controls (n=56). (C) Association between CA-DNA and ex vivo IFN-g responses
to stimulation with Imiquimod and S. pneumoniae in PLHIV. (D) Association between CA-DNA and circulating IFN-g in PLHIV. (E) Association between Th17
percentages and circulating IL-17A in PLHIV. (F) Heatmap of B cell percentages (total n=28) that were significantly correlated with IgM or IgG levels in PLHIV; WBC
subsets that showed no significant correlations with any of the parameters (n=21) have been removed from the figure. Inverse-rank transformed data were analyzed
using linear regression analyses and corrected for sampling time. For cohort comparisons, data were corrected for age, sex, sampling time, season and the CD4+
and CD8+ cell percentages. For color coding of the FDR-adjusted p-values see legend. CA-DNA, CD4-cell-associated HIV-1 DNA; HC, healthy control; IFN-g,
interferon gamma; Ig, immunoglobulin; IL-17(A), interleukin 17(A); IL-22, interleukin 22; Mem Tc, CD4+ memory T cell; NK(T) cells, natural killer (T) cells; PBMC,
peripheral blood mononuclear cell; PLHIV, people living with HIV; sCD14, soluble CD14; Th17 percentages, T-helper 17 cell percentages (Mem Tc CCR6+ CXCR3-
CCR4+ as percentage of CD4+ Mem Tc); WBC, white blood cell.April 2021 | Volume 12 | Article 661990
Van de Wijer et al. Generalized Immune Dysregulation in HIVour data, might be compromised in chronic stable PLHIV. B/T
cell interactions take place in the germinal centers in lymph
nodes and are orchestrated by follicular Th cells (Tfh) (64). As
these cells are known to be highly permissive to HIV infection
and serve as reservoirs during chronic infection, they could
potentially explain these disrupted B/T cell interactions (64–
66). Clinically, compromised B/T cells interactions may
contribute to impaired immune responses to vaccination as
well as increased risks for infections, such as invasive
pneumococcal disease (5, 67). Finally, improvement of B/T
cell communication is crucial for the development of broadly
neutralizing antibodies and thus functional cure in PLHIV (68).
Our findings support the relevance of new immune
modulating strategies in ART-treated PLHIV. Examples of
interventions with potent anti-inflammatory properties in
PLHIV include the IL-1b-inhibiting agent canakinumab (69)
and the epigenetic modifier panobinostat (HDACi) (70, 71).
Moreover, checkpoint inhibitors (e.g. those targeting PD1, PD-
L1, and CTLA4) have been shown to, transiently, reverse
latency of the viral reservoir, to restore cytotoxic T cell
functions (72–75), and to enhance B-cell germinal responses
to HIV-1 envelope vaccines (76). Further research is required to
establish whether these agents are safe and effective long-term
options to mitigate inflammation and to reverse immune
exhaustion and HIV latency in stable HIV infection.
Several limitations should be considered when interpreting
our data. First, the observational study design limits causal
inferences. Second, generalizability of our findings to women,
children and non-European populations requires further
studying. Third, participants from the HIV cohort were older
and more often male and age and sex both have known effects
on the immune system (19, 21) To adjust for these differences,
we used multivariable regression models which allowed us to
take into account the effects of these independent predictors
(age and sex) on our outcome of interest (HIV status). Fourth,
we used a predefined set of markers and flow cytometry panels.
While this standardized approach enhances validity and
reproducibility and enabled us to compare our results with
those of a large cohort of healthy controls, some interesting
WBC subsets and markers for HIV have not been included (e.g.
Tfh cells, CD38 HLA-DR co-expression, and PD-1/CD57
expression in the context of B/T cell interactions, T-cell
activation, and immune cell exhaustion respectively).
Furthermore, data on intracellular production of IL-17 and
IFN-g in maximally stimulated sorted cell populations (e.g.
Th17 or NK cells) may provide a better understanding of the
changes in cytokine production capacity per WBC subset.
Finally, our WBC data are limited to the peripheral blood
and we have no data on tissue-specific WBC composition (e.g.
lymph nodes or the gut).
In summary, we show that the circulating innate and adaptive
immune cell composition is altered in a large group of PLHIV
receiving cART formore than sixmonths. Furthermore, our findings
suggest that some of the adaptive immune responses (Th17) are
preserved while IFN-g responses are compromised. Our
comprehensive approach provides new insight into the changes inFrontiers in Immunology | www.frontiersin.org 13the immune cell architecture and functional immunity in treated
HIV and highlights associations with the HIV-reservoir, underlining
the need for early cART initiation. Our results are currently validated
and extended in a multi-omics study including 2000 virally
suppressed PLHIV (clinicaltrials.gov identifier: NCT03994835).DATA AVAILABILITY STATEMENT
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